Table 2.
Long-term outcomes of study patients after IPTW.
| Number of Event (%) | HR or SHR (95% CI) | |||||
|---|---|---|---|---|---|---|
| Non-Chronic Use Category | Chronic Use Category | |||||
| Variable | Non-User | New User | Former User | Long-Term User | New User vs. Non-User | Long-Term User vs. Former User |
| 6 month | ||||||
| Primary outcome | ||||||
| Recurrence of ischemic stroke | 13.6 | 13.2 | 15.9 | 14.2 | 0.95 (0.94–0.97) * | 0.87 (0.86–0.88) * |
| Secondary outcome | ||||||
| Cardiovascular death | 2.7 | 5.4 | 2.8 | 4.5 | 2.03 (1.97–2.08) * | 1.62 (1.57–1.67) * |
| All-cause mortality | 4.9 | 6.9 | 5.6 | 7.5 | 1.43 (1.40–1.46) * | 1.35 (1.32–1.38) * |
| New-diagnosedatrial fibrillation | 3.3 | 2.4 | 3.1 | 4.3 | 0.73 (0.70–0.75) * | 1.39 (1.35–1.44) * |
| 2 year | ||||||
| Primary outcome | ||||||
| Recurrence of ischemic stroke | 21.0 | 20.1 | 23.5 | 21.0 | 0.92 (0.91–0.93) * | 0.87 (0.86–0.88) * |
| Secondary outcome | ||||||
| Cardiovascular death | 6.7 | 8.8 | 6.9 | 7.6 | 1.28 (1.26–1.31) * | 1.11 (1.09–1.14) * |
| All-cause mortality | 12.5 | 15.2 | 12.1 | 13.2 | 1.18 (1.17–1.20) * | 1.10 (1.08–1.12) * |
| New-diagnosedatrial fibrillation | 5.1 | 4.8 | 4.2 | 6.7 | 0.91 (0.88–0.93) * | 1.61 (1.57–1.65) * |
Data are presented as frequency (percentage); * p < 0.05.